AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 201 min read$CRSP

Kulkarni Samarth sold $2.4M of CRSP

Kulkarni Samarth (Chief Executive Officer) sold 47,837 shares of CRISPR Therapeutics AG (CRSP) at $49.78 ($2.38M total) on 2026-10-19.

Original reporting
SEC EDGAR · Kulkarni Samarth
Published Oct 20, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRSP
Bearish
high confidence
Mentioned
$CRSP
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

The $2.38 M sale reduces the CEO's ownership by ~13% and may trigger short‑term selling pressure.

02

Market read

Insider sell by the CEO provides fresh material for traders; could influence short‑term price action.

03

What to watch

No 10b5‑1 plan; the sale was not pre‑arranged, suggesting discretionary timing.

Relevance 6/10Novelty 6/10Timing: filed today (Oct 20)

Background

Form 4 filings disclose insider transactions; a CEO sale is closely watched by investors.

Company-level read

Ticker impact

$CRSPBearishHigh confidence
Context

CEO Kulkarni Samarth sold 47,837 shares for $2.38 M, reducing his stake to 311,899 shares.

Expected impact

likely downward pressure as the market prices the insider sell.

Evidence & confidence

Form 4 is a primary source; a $2.4 M sale by the CEO is material and new information.

Market effects

Sector

May raise concerns for the biotech sector if other insiders follow suit.

Regional

Limited to US and European markets where CRISPR trades.

Global

Low; impact confined to CRISPR and its immediate peers.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • person
    Kulkarni Samarth

    Chief Executive Officer of CRISPR Therapeutics AG

  • company
    CRISPR Therapeutics AG

    Biotech firm developing CRISPR‑based gene editing therapies

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRSP insider trading history →

Related articles

OCT 28
$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

stocktwits.com2 min
OCT 24
$CRSPMedAI 8/10

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

CRISPR Therapeutics (CRSP) reports promising Phase 1a trial data for CTX310, a gene-editing therapy for high LDL and TG levels, with potential market of 40M+ U.S. patients. The company also shares Casgevy's rights with Vertex (VRTX). CTX310's Phase 1b results are expected in November. CRISPR's pipeline includes other candidates like CTX611, but faces risks of setbacks and market adoption challenges.

finance.yahoo.com3 min